DEVELOPMENT AND EVALUATION OF ORAL SUSTAINED-RELEASE RANITIDINE DELIVERY SYSTEM BASED ON BACTERIAL NANOCELLULOSE MATERIAL PRODUCED BY KOMAGATAEIBACTER XYLINUS

Objective: The short biological half-life (2-3 h) and low bioavailability (50 %) of ranitidine (RAN) following oral administration favor the development of a controlled release system. This study was aimed to develop and in vitro evaluate oral sustained-release RAN delivery system based on the bacterial nanocellulose material (BNM) produced by Komagataeibacter xylinus (K. xylinus) from selected culture media. Methods: BNMs are biosynthesized by K. xylinus in the standard medium (SM) and coconut water (CW). RAN was loaded in BNMs by the absorption method. The structural and physicochemical properties of BNMs and BNMs-RAN were evaluated via swelling behavior, FTIR, and FESEM techniques. Moreover, the effect of BNMs on RAN release profile and release kinetics was analyzed and evaluated. Results: The amount of loaded RAN or entrapment efficacy for BNM-CW is higher than for BNM-SM. The BNM-SM-RAN and BNM-CW-RAN exhibited a decreased initial burst release system followed by a prolonged RAN release up to 24 h in relation to the commercial tablets containing RAN. The RAN release from these formulations was found higher in the SGF medium than that of in SIF medium. RAN released from these formulations was found to follow the Korsmeyer-Peppas model and diffusion sustained drug release mechanism. The sustained release of RAN from BNM-SM-RAN was slower than for RAN from BNM-CW-RAN, but the mechanism of sustained RAN release was the same. Conclusion: Oral sustained-release RAN delivery system based on BNMs was successfully prepared and evaluated for various in vitro parameters. The biopolymers like BNM-SM and BNM-CW could be utilized to develop oral sustained RAN release dosage form

Ecommerce risk management: analysing the case Vietnam Airlines incident

E-Commerce is the purchase and sale of goods, services and exchange of information based on communications networks and the Internet. Information, information systems, computers, computer networks, and other electronic means play an especially important role. These objects are valuable assets and targeted attacks by cybercriminals. E-commerce risk management is to protect the development of e-commerce. It includes setting information security objectives, assessing vulnerabilities, threats and attacks, and selecting countermeasures. The paper presents the theory of e-commerce risk management, analysing the Vietnam Airlines e-commerce risk management case, using the DREAD model. The paper provides the discussions and short recommendations to other enterprises in e-commerce risk management nowadays

Safety and efficacy of fluoxetine on functional outcome after acute stroke (AFFINITY): a randomised, double-blind, placebo-controlled trial

Background Trials of fluoxetine for recovery after stroke report conflicting results. The Assessment oF FluoxetINe In sTroke recoverY (AFFINITY) trial aimed to show if daily oral fluoxetine for 6 months after stroke improves functional outcome in an ethnically diverse population. Methods AFFINITY was a randomised, parallel-group, double-blind, placebo-controlled trial done in 43 hospital stroke units in Australia (n=29), New Zealand (four), and Vietnam (ten). Eligible patients were adults (aged ≥18 years) with a clinical diagnosis of acute stroke in the previous 2–15 days, brain imaging consistent with ischaemic or haemorrhagic stroke, and a persisting neurological deficit that produced a modified Rankin Scale (mRS) score of 1 or more. Patients were randomly assigned 1:1 via a web-based system using a minimisation algorithm to once daily, oral fluoxetine 20 mg capsules or matching placebo for 6 months. Patients, carers, investigators, and outcome assessors were masked to the treatment allocation. The primary outcome was functional status, measured by the mRS, at 6 months. The primary analysis was an ordinal logistic regression of the mRS at 6 months, adjusted for minimisation variables. Primary and safety analyses were done according to the patient's treatment allocation. The trial is registered with the Australian New Zealand Clinical Trials Registry, ACTRN12611000774921. Findings Between Jan 11, 2013, and June 30, 2019, 1280 patients were recruited in Australia (n=532), New Zealand (n=42), and Vietnam (n=706), of whom 642 were randomly assigned to fluoxetine and 638 were randomly assigned to placebo. Mean duration of trial treatment was 167 days (SD 48·1). At 6 months, mRS data were available in 624 (97%) patients in the fluoxetine group and 632 (99%) in the placebo group. The distribution of mRS categories was similar in the fluoxetine and placebo groups (adjusted common odds ratio 0·94, 95% CI 0·76–1·15; p=0·53). Compared with patients in the placebo group, patients in the fluoxetine group had more falls (20 [3%] vs seven [1%]; p=0·018), bone fractures (19 [3%] vs six [1%]; p=0·014), and epileptic seizures (ten [2%] vs two [<1%]; p=0·038) at 6 months. Interpretation Oral fluoxetine 20 mg daily for 6 months after acute stroke did not improve functional outcome and increased the risk of falls, bone fractures, and epileptic seizures. These results do not support the use of fluoxetine to improve functional outcome after stroke

STUDY ON FORMULATION OF BACTERIAL CELLULOSE NANOFIBERS-COATED NANOLIPOSOMES CONTAINING PACLITAXEL FOR ORAL ADMINISTRATION

Objective: The low oral bioavailability of paclitaxel (PAC) because of its limited aqueous solubility and poor intestinal permeability after being administered orally suggests the need for a sustained release system. The aim of this study is to produce and evaluate in vitro a nanoliposome system that carries paclitaxel (BCN-LIP-PAC) for oral administration. Methods: Thin-film evaporation and electrostatic deposition methods were used to obtain LIP-PAC and BCN-LIP-PAC. Particle size, polydispersity index (PDI), zeta potential, morphological analysis, entrapment efficiency percentage (EE%), and in vitro dissolution studies were used to characterize the developed systems.  Results: The nano-range sizes of LIP-PAC and BCN-LIP-PAC (0.1 % BCN) were 112±4.2 nm and 154±6.4 nm, respectively, where EE % were 80.6±2.3 % and 84.6±1.7 %, respectively. BCN-LIP-PAC exhibited good stability in simulated gastrointestinal fluids. The drug release experiments conducted in vitro showed that BCN-LIP-PAC had obvious sustained release behaviors when compared to LIP-PAC. Furthermore, the release rate of PAC from all LIP-PAC and BCN-LIP-PAC was higher in SIF than in SGF. Conclusion: The preparation, characterization, and evaluation of BCN-LIP-PAC (0.1 % BCN) for oral PAC delivery were all successful. In conclusion, the approach presented herein is a promising option for delivering oral sustained-release PAC

Modification of graphene oxide and its effect on properties of natural rubber/graphene oxide nanocomposites

Modification of graphene oxide (GO) by vinyltriethoxysilane (VTES) was investigated to study the effect of silanized GO on radical graft copolymerization of GO onto deproteinized natural rubber (DPNR). The modified GO, GO-VTES (a and b), was characterized by X-ray diffraction (XRD), Fourier-transform infrared spectroscopy, contact angle, thermal gravimetric analysis, and scanning electron microscopy. The XRD results showed the appearance of an amorphous region of silica particles at a diffraction angle of 22°. The formation of silica was investigated by 29Si NMR, and it was found that the hydrolysis and condensation of VTES proceed more completely in basic conditions than in acidic conditions. The silica content of GO-VTES(b) was 43%, which is higher than that of GO-VTES(a) (8%). Morphology of silica was observed by SEM. The DPNR/GO-VTES nanocomposites prepared with the same amount of GO, GO-VTES(a), and GO-VTES(b) were characterized with tensile tests and dynamic mechanical tests. The stress at break of DPNR/GO-VTES(a) and DPNR/GO-VTES(b) was 5.2 MPa and 4.3 MPa, respectively, which were lower than that of DPNR/GO. However, it exhibited higher stress at small strains and higher storage modulus than DPNR/GO

Raphiocarpus Raphiocarpus taygiangensis (Gesneriaceae), a new species from Central Vietnam

Raphiocarpus taygiangensis, a new species of Gesneriaceae from Tay Giang District, Quang Nam Province, Central Vietnam, is here described and illustrated. The new species is diagnostic by the combination of its long stem, serrate leaf margin, purple spots, purple longitudinal lines, and glandular short hairs inside corolla. Morphological distinctiveness of the new species from the most similar species, Raphiocarpus axillaris, is discussed. The conservation status of this species is estimated as Vulnerable (VU D2) according to the IUCN Red List Criteria

Design and fabrication of highly reducible PtCo particles supported on graphene-coated ZnO

International audienc

Low-Dimensional CsPbBr₃@CoBr₂ Super-Nanowire Structure for Perovskite/PMMA Composite with Highly Blue Emissive Performance

In this study, low-dimensional CsPbBr3@CoBr2 super-nanowire (SNW) structures were synthesized via a one-pot heating strategy for highly blue emissions. By introducing CoBr2 to CsPbBr3 precursors, the shape of perovskite nanocrystals was changed from cuboids to a super-nanowire structure, as revealed through a transmission electron microscope. SNWs were formed from stacked segments of nano-plates (lateral dimension of 10–12 nm and thickness of ~2.5 nm) with lengths of several microns. The fabricated sample absorbs light at a wavelength of 3@CoBr2 SNWs highly promising for a range of photolumicescence applications, such as a high color rendering index lighting and transparent blue emissive screen

Raphiocarpus taygiangensis (Gesneriaceae), a new species from central Vietnam

Raphiocarpus taygiangensis, a new species of Gesneriaceae family discovered in Tay Giang District, Quang Nam Province, Central Vietnam, is here described and illustrated. The new species is diagnosed by the combination of its stem up to 2 m long, sericeous hairs on young stem, leaf petiole and adaxial mid-vein, sparsely and minutely serrate leaf margin, axillary inflorescence spreading along stem, sparsely long gland-tipped hairs on peduncle, pedicel, calyx, outside corolla and pistil, calyx 5-disparted from base, purplish white flower with purple stripes inside corolla tube, and dish-shaped stigma formed by 2 semi-orbicular lobes horizontally expanding. Distinct features of the new species and its morphologically closest congener, Rhaphiocarpus axillaris, are compared and discussed. The conservation status of the described species is estimated as Vulnerable (VU D2) according to the IUCN Red List Criteria

Twelve-Month Outcomes of the AFFINITY Trial of Fluoxetine for Functional Recovery After Acute Stroke: AFFINITY Trial Steering Committee on Behalf of the AFFINITY Trial Collaboration

Background and Purpose: The AFFINITY trial (Assessment of Fluoxetine in Stroke Recovery) reported that oral fluoxetine 20 mg daily for 6 months after acute stroke did not improve functional outcome and increased the risk of falls, bone fractures, and seizures. After trial medication was ceased at 6 months, survivors were followed to 12 months post-randomization. This preplanned secondary analysis aimed to determine any sustained or delayed effects of fluoxetine at 12 months post-randomization. Methods: AFFINITY was a randomized, parallel-group, double-blind, placebo-controlled trial in adults (n=1280) with a clinical diagnosis of stroke in the previous 2 to 15 days and persisting neurological deficit who were recruited at 43 hospital stroke units in Australia (n=29), New Zealand (4), and Vietnam (10) between 2013 and 2019. Participants were randomized to oral fluoxetine 20 mg once daily (n=642) or matching placebo (n=638) for 6 months and followed until 12 months after randomization. The primary outcome was function, measured by the modified Rankin Scale, at 6 months. Secondary outcomes for these analyses included measures of the modified Rankin Scale, mood, cognition, overall health status, fatigue, health-related quality of life, and safety at 12 months. Results: Adherence to trial medication was for a mean 167 (SD 48) days and similar between randomized groups. At 12 months, the distribution of modified Rankin Scale categories was similar in the fluoxetine and placebo groups (adjusted common odds ratio, 0.93 [95% CI, 0.76–1.14]; P =0.46). Compared with placebo, patients allocated fluoxetine had fewer recurrent ischemic strokes (14 [2.18%] versus 29 [4.55%]; P =0.02), and no longer had significantly more falls (27 [4.21%] versus 15 [2.35%]; P =0.08), bone fractures (23 [3.58%] versus 11 [1.72%]; P =0.05), or seizures (11 [1.71%] versus 8 [1.25%]; P =0.64) at 12 months. Conclusions: Fluoxetine 20 mg daily for 6 months after acute stroke had no delayed or sustained effect on functional outcome, falls, bone fractures, or seizures at 12 months poststroke. The lower rate of recurrent ischemic stroke in the fluoxetine group is most likely a chance finding. REGISTRATION: URL: http://www.anzctr.org.au/ ; Unique identifier: ACTRN12611000774921